Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine oral - INNOPHARMAX

Next Previous
Drug Profile

Gemcitabine oral - INNOPHARMAX

Alternative Names: D07001; D07001-F4; Gemcitabine HCl - INNOPHARMAX; Inno-D07001

Latest Information Update: 09 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INNOPHARMAX
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Biliary cancer
  • No development reported Gastrointestinal cancer; Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 01 Oct 2024 INNOPHARMAX plans a phase III trial for Biliary cancer (Combination therapy, Second-line therapy, late-stage disease) in Taiwan (PO, Capsule) in April 2025 (NCT06622057)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO, Capsule)
  • 30 Dec 2022 Discontinued - Phase-I for Lymphoma (Late-stage disease, Second-line therapy or greater) in Taiwan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top